Obefazimod

DB14828InvestigationalSmall molecule

ABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).

Mechanism: Pharmacologically active on Nuclear cap-binding protein subunit 2 and Nuclear cap-binding protein subunit 1
Curator reviewed
Formula / weight: C₁₆H₁₀ClF₃N₂O · 338.71 g/mol (avg)
Code names: ABX-464

Resolves to

Compound

UNII26RU378B9VCAS1258453-75-6ChEMBLCHEMBL4297344

Structure

InChIKeyOZOGDCZJYVSUBR-UHFFFAOYSA-NSMILESFC(F)(F)OC1=CC=C(NC2=CC=C3C=CC=C(Cl)C3=N2)C=C1

Targets

P52298NCBP2Q09161NCBP1

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Obefazimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account